chris lord Search Results


cas9 viral particles  (Addgene inc)
96
Addgene inc cas9 viral particles
Functional Impact of RAS/RAF Mutations and NF1 Inactivation on Cetuximab Sensitivity (A) Western blot of BRAF and KRAS mutants in DiFi cells. Quantification of pERK signal relative to total ERK as a loading control, and normalized to luciferase control. (B) Western blot following NF1 (siNF1) or control (siCON) small interfering RNA in LIM1215 cells. Quantification of pERK signal relative to total ERK, and normalized to untreated control. (C) Sanger sequencing of LIM1215 cells transduced with two CRISPR guide RNAs against NF1 . Guide sequences are highlighted by a black bar. (D) Western blot of CRISPR-inactivated NF1 and <t>Cas9</t> control cells with/without 24 h cetuximab treatment. Quantification of pERK signal relative to total ERK and normalized to untreated Cas9 control. (E) Growth of CRISPR-inactivated NF1 and Cas9 control cells by crystal violet staining (left) and quantification (right).
Cas9 Viral Particles, supplied by Addgene inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cas9 viral particles/product/Addgene inc
Average 96 stars, based on 1 article reviews
cas9 viral particles - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier
chris lord  (Addgene inc)
93
Addgene inc chris lord
Functional Impact of RAS/RAF Mutations and NF1 Inactivation on Cetuximab Sensitivity (A) Western blot of BRAF and KRAS mutants in DiFi cells. Quantification of pERK signal relative to total ERK as a loading control, and normalized to luciferase control. (B) Western blot following NF1 (siNF1) or control (siCON) small interfering RNA in LIM1215 cells. Quantification of pERK signal relative to total ERK, and normalized to untreated control. (C) Sanger sequencing of LIM1215 cells transduced with two CRISPR guide RNAs against NF1 . Guide sequences are highlighted by a black bar. (D) Western blot of CRISPR-inactivated NF1 and <t>Cas9</t> control cells with/without 24 h cetuximab treatment. Quantification of pERK signal relative to total ERK and normalized to untreated Cas9 control. (E) Growth of CRISPR-inactivated NF1 and Cas9 control cells by crystal violet staining (left) and quantification (right).
Chris Lord, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chris lord/product/Addgene inc
Average 93 stars, based on 1 article reviews
chris lord - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
aspergillus bicolor christensen et states  (ATCC)
N/A
An ampoule containing viable cells (may include spores and mycelia) suspended in cryoprotectant.
   Buy from Supplier

Image Search Results


Functional Impact of RAS/RAF Mutations and NF1 Inactivation on Cetuximab Sensitivity (A) Western blot of BRAF and KRAS mutants in DiFi cells. Quantification of pERK signal relative to total ERK as a loading control, and normalized to luciferase control. (B) Western blot following NF1 (siNF1) or control (siCON) small interfering RNA in LIM1215 cells. Quantification of pERK signal relative to total ERK, and normalized to untreated control. (C) Sanger sequencing of LIM1215 cells transduced with two CRISPR guide RNAs against NF1 . Guide sequences are highlighted by a black bar. (D) Western blot of CRISPR-inactivated NF1 and Cas9 control cells with/without 24 h cetuximab treatment. Quantification of pERK signal relative to total ERK and normalized to untreated Cas9 control. (E) Growth of CRISPR-inactivated NF1 and Cas9 control cells by crystal violet staining (left) and quantification (right).

Journal: Cancer Cell

Article Title: Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

doi: 10.1016/j.ccell.2019.05.013

Figure Lengend Snippet: Functional Impact of RAS/RAF Mutations and NF1 Inactivation on Cetuximab Sensitivity (A) Western blot of BRAF and KRAS mutants in DiFi cells. Quantification of pERK signal relative to total ERK as a loading control, and normalized to luciferase control. (B) Western blot following NF1 (siNF1) or control (siCON) small interfering RNA in LIM1215 cells. Quantification of pERK signal relative to total ERK, and normalized to untreated control. (C) Sanger sequencing of LIM1215 cells transduced with two CRISPR guide RNAs against NF1 . Guide sequences are highlighted by a black bar. (D) Western blot of CRISPR-inactivated NF1 and Cas9 control cells with/without 24 h cetuximab treatment. Quantification of pERK signal relative to total ERK and normalized to untreated Cas9 control. (E) Growth of CRISPR-inactivated NF1 and Cas9 control cells by crystal violet staining (left) and quantification (right).

Article Snippet: LIM1215 cells were transduced with Cas9 viral particles (a gift from Feifei Song, Stephen Pettitt and Chris Lord, derived from lentiCas9-Blast (Addgene # 52962, a gift from Feng Zhang)) in the presence of Polybrene (8 μg/mL) and selected with 5 μg/mL Blasticidin to create constitutively expressing Cas9 lines, confirmed by Western blotting using Cas9 (7A9-3A3) antibody (Cell Signalling Technologies #14697).

Techniques: Functional Assay, Western Blot, Control, Luciferase, Small Interfering RNA, Sequencing, Transduction, CRISPR, Staining

Journal: Cancer Cell

Article Title: Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer

doi: 10.1016/j.ccell.2019.05.013

Figure Lengend Snippet:

Article Snippet: LIM1215 cells were transduced with Cas9 viral particles (a gift from Feifei Song, Stephen Pettitt and Chris Lord, derived from lentiCas9-Blast (Addgene # 52962, a gift from Feng Zhang)) in the presence of Polybrene (8 μg/mL) and selected with 5 μg/mL Blasticidin to create constitutively expressing Cas9 lines, confirmed by Western blotting using Cas9 (7A9-3A3) antibody (Cell Signalling Technologies #14697).

Techniques: Control, Recombinant, Sequencing, Software